Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Aug 18;59(9):e0109421.
doi: 10.1128/JCM.01094-21. Epub 2021 Aug 18.

Stenotrophomonas maltophilia Susceptibility Testing Challenges and Strategies

Daniel D Rhoads  1
Affiliations

Stenotrophomonas maltophilia Susceptibility Testing Challenges and Strategies

Daniel D Rhoads. J Clin Microbiol. .

Abstract

Stenotrophomonas maltophilia is intrinsically resistant to many beta-lactam antibiotics, including carbapenems, and is resistant to aminoglycosides, which limits the therapeutic repertoire for managing S. maltophilia infections. Additionally, employing automated in vitro susceptibility testing of S. maltophilia is challenging because commercial test systems' performance is limited (A. Khan, C. A. Arias, A. Abbott, J. Dien Bard, et al., J Clin Microbiol 59:e00654-21, 2021, https://doi.org/10.1128/JCM.00654-21). This commentary will briefly discuss the opportunity to use automated commercial susceptibility testing systems with S. maltophilia, with a focus on how to implement their use practically while mitigating risk of error.

PubMed Disclaimer

Comment on

References

    1. Nicodemo AC, Paez JI. 2007. Antimicrobial therapy for Stenotrophomonas maltophilia infections. Eur J Clin Microbiol Infect Dis 26:229–237. doi: 10.1007/s10096-007-0279-3. - DOI - PubMed
    1. Wang Y, He T, Shen Z, Wu C. 2018. Antimicrobial resistance in Stenotrophomonas spp. Microbiol Spectr 6. doi: 10.1128/microbiolspec.ARBA-0005-2017. - DOI - PMC - PubMed
    1. Shah MD, Coe KE, El Boghdadly Z, Wardlow LC, Dela-Pena JC, Stevenson KB, Reed EE. 2019. Efficacy of combination therapy versus monotherapy in the treatment of Stenotrophomonas maltophilia pneumonia. J Antimicrob Chemother 74:2055–2059. doi: 10.1093/jac/dkz116. - DOI - PubMed
    1. Guerci P, Bellut H, Mokhtari M, Gaudefroy J, Mongardon N, Charpentier C, Louis G, Tashk P, Dubost C, Ledochowski S, Kimmoun A, Godet T, Pottecher J, Lalot JM, Novy E, Hajage D, Bouglé A, AZUREA research network. 2019. Outcomes of Stenotrophomonas maltophilia hospital-acquired pneumonia in intensive care unit: a nationwide retrospective study. Crit Care 23:371. doi: 10.1186/s13054-019-2649-5. - DOI - PMC - PubMed
    1. Ko JH, Kang CI, Cornejo-Juárez P, Yeh KM, Wang CH, Cho SY, Gözel MG, Kim SH, Hsueh PR, Sekiya N, Matsumura Y, Lee DG, Cho SY, Shiratori S, Kim YJ, Chung DR, Peck KR. 2019. Fluoroquinolones versus trimethoprim-sulfamethoxazole for the treatment of Stenotrophomonas maltophilia infections: a systematic review and meta-analysis. Clin Microbiol Infect 25:546–554. doi: 10.1016/j.cmi.2018.11.008. - DOI - PubMed

LinkOut - more resources